Results 61 to 70 of about 33,272 (203)

Hiding in plain sight: DICER1‐associated yolk sac tumour masquerading as an endometrioid carcinoma of the ovary

Histopathology, EarlyView.
Lili Fu, Afrida Ahmed, Celine Domecq, Elizabeth N Skinner, William D Foulkes   +4 more
wiley   +1 more source

IgG4‐Related Disease Overlapping With Anti‐Acetylcholine Receptor Antibody–Positive Myasthenia Gravis

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background IgG4‐related disease (IgG4‐RD) is a systemic, immune‐mediated, fibroinflammatory disorder with multiorgan involvement and variable clinical presentation, often creating diagnostic difficulty. Myasthenia gravis (MG) is an antibody‐mediated autoimmune disorder of the neuromuscular junction, most commonly associated with anti ...
Yumiko Yoshida, Ayami Okuzumi, Yuka Hosaka, Yuji Tomizawa, Taku Hatano   +4 more
wiley   +1 more source

Multiple Oral and Eyelid Nodules in a Pediatric Patient

Oral Diseases, EarlyView.
Caique Mariano Pedroso, Paulo Victor Mendes Penafort, Patrícia Vitor de Souza, Fernanda M. Pascon, Regina Maria Punppin‐Rontani, Beatriz Frolini Paulo Cherve, Rachel Marinho Robim, Regina Maria Holanda de Mendonça, Marcio Ajudarte Lopes, Pablo Agustin Vargas, Alan Roger Santos‐Silva   +10 more
wiley   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Tongue Nodule Affecting Breastfeeding

Oral Diseases, EarlyView.
Giuliano Saraceni Issa Cossolin, Heitor Albergoni Silveira, Ana Paula Abreu Vieira Alves, Carla Gabriela Ermacora, José Burgos Ponce, Camila Lopes Cardoso   +5 more
wiley   +1 more source

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (
Erika Soga, Go Noguchi, Kota Kobayashi, Rio Shibata, Ryosuke Jikuya, Tomoyuki Tatenuma, Mitsuru Komeya, Hiroki Ito, Hisashi Hasumi, Kazuhide Makiyama   +9 more
wiley   +1 more source

Identifying Failure Predictors in Thyroid Nodule Radiofrequency Ablation Using Multivariate Analysis: A Single‐Centre Experience

Clinical Endocrinology, Volume 105, Issue 1, Page 85-92, July 2026.
ABSTRACT Background Radiofrequency ablation (RFA) has become an established minimally invasive treatment for benign thyroid nodules (BTN), offering excellent safety and efficacy. However, factors predicting treatment success and post‐procedural thyroid dysfunction remain incompletely understood.
Shmuel Wechsler, Tanya Shcherbaeva, Jacob Pitaro, Limor Muallem Kalmovich   +3 more
wiley   +1 more source

Comparative Analysis of Incidental and Non‐Incidental Papillary Thyroid Microcarcinoma Outcomes: Implications on Management Recommendations

Clinical Endocrinology, Volume 105, Issue 1, Page 100-107, July 2026.
ABSTRACT Introduction Papillary thyroid microcarcinomas (PTMC) are defined by the World Health Organisation (WHO) as tumours measuring ≤ 10 mm. Incidental PTMCs, or lesions discovered postoperatively on histological examination, are less extensively studied compared with lesions diagnosed preoperatively through cytology, particularly in terms of ...
Emma A. Finnegan, Justin M. Hintze, Anne McGowan, James Gibney, Conall W. R. Fitzgerald, John Kinsella, Marie Louise Healy   +6 more
wiley   +1 more source

Analysis of PLEKHS1 promoter mutation in preoperative thyroid nodule samples. [PDF]

Cancer Cytopathol
Azad S, Graham TE, Levy S, Velanzuela-Sheker E, Bimston D, Ferenczi A, Chen Y, Alshalalfa M, Hao Y, Klopper JP, Kloos RT, Kotwal A.   +11 more
europepmc   +1 more source

From Lobectomy to Completion Thyroidectomy: A Cohort Study and Systematic Review

Clinical Endocrinology, Volume 105, Issue 1, Page 108-115, July 2026.
ABSTRACT Introduction The suggested management of thyroid cancer has been revised in the 2015 American Thyroid Association Management Guidelines, suggesting thyroid lobectomy alone for low‐risk thyroid cancer. However, precise patient selection is essential to identify who may need completion thyroidectomy (CT), avoiding the burden of a second surgery.
Idit Tessler, Tzahi Yamin, Liroy Caracucli, Josh Krasner, Shaked Shivatzki, Nir A. Gecel, Eran E. Alon, Galit Avior   +7 more
wiley   +1 more source